Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N2O2.C2H4O2 |
Molecular Weight | 206.2395 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.NCCCC[C@H](N)C(O)=O
InChI
InChIKey=RRNJROHIFSLGRA-JEDNCBNOSA-N
InChI=1S/C6H14N2O2.C2H4O2/c7-4-2-1-3-5(8)6(9)10;1-2(3)4/h5H,1-4,7-8H2,(H,9,10);1H3,(H,3,4)/t5-;/m0./s1
DescriptionSources: https://www.nap.edu/read/10490/chapter/12Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.
CNS Activity
Originator
Sources: https://www.drugs.com/npp/lysine.html
Curator's Comment: Lysine was first isolated from casein (a milk phosphoprotein) in 1889 by the German dentist Heinrich Drechsel
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616 |
|||
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | L-LYSINE MONOHYDRATE Approved UseLysine has been studied for the prevention and treatment of herpes infections and cold sores. |
|||
Primary | L-LYSINE MONOHYDRATE Approved UseLysine supplements may relieve effort-related angina pectoris. |
|||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine increases the intestinal absorption and reduces the renal elimination of calcium. |
||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist |
||
Palliative | L-LYSINE MONOHYDRATE Approved UseLysine acetylsalicylate has been used to detoxify the body after heroin use. |
|||
Primary | NEOPROFEN Approved UseNeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
Dose-dependent protein adduct formation in kidney, liver, and blood of rats and in human blood after perchloroethene inhalation. | 1999 Mar |
|
Detection of rare malignant cells and their apoptotic fragments in cerebrospinal fluid. | 2000 Oct 7 |
|
Differences in sialic acid density in pathogenic and non-pathogenic Aspergillus species. | 2001 Apr |
|
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli. | 2001 Apr 17 |
|
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner. | 2001 Apr 27 |
|
Ethanol production from wheat straw hemicellulose hydrolysate by Pichia stipitis. | 2001 Apr 27 |
|
The effect of protease inhibitors on the two-dimensional electrophoresis pattern of red blood cell membranes. | 2001 Feb |
|
Combination of HPLC and solid-phase binding assay for isolation and purification of MHC class I and associated peptides using a bladder tumour cell line. | 2001 Feb |
|
Development of xylose-fermenting yeast Pichia stipitis for ethanol production through adaptation on hardwood hemicellulose acid prehydrolysate. | 2001 Feb |
|
Affinity purification of Csk protein tyrosine kinase based on its catalytic requirement for divalent metal cations. | 2001 Feb |
|
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. | 2001 Feb |
|
Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin. | 2001 Feb 16 |
|
ESR detection of intraphagosomal superoxide in polymorphonuclear leukocytes using 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-N-oxide. | 2001 Jan |
|
Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation. | 2001 Jan |
|
Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. | 2001 Jan |
|
Identification of lysine 346 as a functionally important residue for pyridoxal 5'-phosphate binding and catalysis in lysine 2, 3-aminomutase from Bacillus subtilis. | 2001 Jan 16 |
|
Panaxagin, a new protein from Chinese ginseng possesses anti-fungal, anti-viral, translation-inhibiting and ribonuclease activities. | 2001 Jan 5 |
|
Investigating the surface expression of the renal type IIa Na+/Pi-cotransporter in Xenopus laevis oocytes. | 2001 Mar 1 |
|
Effects of initial particle size on the tableting properties of L-lysine monohydrochloride dihydrate powder. | 2001 Mar 14 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.nap.edu/read/10490/chapter/12
Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616
In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TTL6G7LIWZ
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
SUB127497
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104640
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
100000091744
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
DBSALT001763
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
TTL6G7LIWZ
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
104152
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
1371501
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
260-664-4
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
6537
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
4453
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
57282-49-2
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
SUB127496
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
SUB21782
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
C66045
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY | |||
|
DTXSID80886223
Created by
admin on Fri Dec 15 15:20:00 GMT 2023 , Edited by admin on Fri Dec 15 15:20:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD